Spero Therapeutics Appoints Ian A. Critchley, Ph.D., as Head of Clinical Microbiology

Building organization to support SPR994 in Phase 3 and beyond, and robust pipeline CAMBRIDGE, Mass. , April 12, 2018 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel

READ FULL TEXT

Leave a Reply

Your email address will not be published.